Ticker Symbol: CUR
QUEBEC CITY, May 1 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, will be presenting at two conferences next week. Mr. John Schafer, President and Chief Executive Officer, will take the opportunity to update the participants on the Company's business and strategy for the upcoming months, the status of the product pipeline as well as other topics of interest.
Mr. Schafer will first present at BioFinance, Canadian Life Science industry's leading investor conference. This event will be held at the Toronto Marriott Eaton Center on May 7 at 10:00 AM (ET). Attendees at this conference include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and scientific and medical experts from around the world.
On May 8, Mr. Schafer will be presenting to the business community of Montreal (Quebec), at a conference hosted by the Association de la recherche industrielle du Quebec (ADRIQ) in collaboration with Pole Quebec-Chaudiere-Appalaches. The event will take place at 11:30 AM (ET) at the Mount Stephen Club.
The presentations will be available afterwards on DiagnoCure's website at www.diagnocure.com.
DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit www.diagnocure.com.
This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.